Bavarian Nordic uses monkeypox win to expand travel vaccines portfolio

15 February 2023

Denmark’s Bavarian Nordic (OMX: BAVA), which has won a number of significant contracts for its smallpox vaccine Imvanex that has also shown efficacy against monkeypox, an infectious disease that has been spreading strongly, is now taking advantage of its windfall to expand its travel vaccines portfolio.

Bavarian Nordic said today that it has entered into an agreement with Emergent BioSolutions (NYSE: EBS) to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase III vaccine candidate for the prevention of Chikungunya virus.

The total transaction value of the deal is $380 million, including $270 million in an upfront payment and up to $110 million in future conditional milestone payments. The acquisition also includes facilities and key personnel related to the acquired assets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK